CD274 and squamous cell carcinoma: For the NSCLC population in China, a previous small-scale study with surgically staged I-III samples showed that PD-L1 expression assessed using the PD-L1 IHC 22C3 antibody varied from 4.1% in adenocarcinomas to 34.3% in squamous cell carcinomas 17.